Xin Zhang

机构：Bayer (Switzerland) · ORCID：0000-0001-5008-0879

发表论文 51 篇 · 总被引 647 次 · h-index 11

代表论文

• Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial (2024 · The Lancet · 被引 118)
• Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration (2025 · Ophthalmology · 被引 25)
• Mechanism of action of the Banxia–Xiakucao herb pair in sleep deprivation: New comprehensive evidence from network pharmacology, transcriptomics and molecular biology experiments (2024 · Journal of Ethnopharmacology · 被引 14)
• Intravitreal Aflibercept 8 mg for Diabetic Macular Edema (2025 · Ophthalmology · 被引 13)
• Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis (2025 · Ophthalmology and Therapy · 被引 13)
• pH‐Responsive Engineered Exosomes Enhance Endogenous Hyaluronan Production by Reprogramming Chondrocytes for Cartilage Repair (2025 · Advanced Healthcare Materials · 被引 12)